Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 5, 2026 (Event Date)
Reporting Period: The filing covers the pricing of a public offering on March 5, 2026, and its closing on March 9, 2026.
Key Financial Metrics
This filing details a capital raise rather than operational financial performance. Key metrics include:
- Gross Proceeds: Approximately $3.5 million.
- Securities Issued: 2,238,800 shares of Common Stock and pre-funded warrants to purchase up to 4,761,200 shares of Common Stock.
- Placement Agent Fees: 4.0% cash fee plus 1.00% non-accountable expenses fee of gross proceeds.
- Pre-Funded Warrant Exercise Price: $0.001 per share.
Note: The filing does not provide data on revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the expansion of the company's capital base through the issuance of new equity and pre-funded warrants. The company entered into a Securities Purchase Agreement and a Placement Agency Agreement with E.F. Hutton & Co. Additionally, executive officers and directors entered into 30-day lock-up agreements restricting the sale of Common Stock and Common Stock Equivalents.
Guidance, Outlook, and Risks
Management Commentary: The offering was conducted on a reasonable best-efforts basis. The company has agreed to restrictions on issuing additional Common Stock or Common Stock Equivalents for 30 days following the closing.
Terms and Contingencies:
- Beneficial Ownership Limitation: Holders cannot exercise warrants if it results in beneficial ownership exceeding 4.99% (or 9.99% at election) of outstanding shares, unless 61 days' prior notice is given to adjust the limit.
- Adjustments: Exercise price and share counts are subject to adjustment for stock dividends, splits, or reorganizations.
Risks: The filing does not explicitly list new risk factors beyond standard contractual restrictions and the dilutive nature of the offering.
Investor Verification Checklist
- Verify the final net proceeds after deducting the 5% total placement agent fees and other offering expenses.
- Confirm the exact number of shares outstanding post-closing to calculate the dilution impact of the 2,238,800 new shares and potential warrant exercises.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and representations.
- Monitor the 30-day lock-up period expiration for potential selling pressure from insiders.
- Check subsequent filings for the use of proceeds, as this 8-K does not specify the intended allocation of the $3.5 million.